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Abstract
Background: Multivessel disease (MVD) is a significant risk factor in patients with acute ST-segment 
elevation myocardial infarction (STEMI). Whether the presence of chronic total occlusion (CTO) poses 
an additional hazard is still unknown. The objective of this study was to evaluate the impact of CTO 
on survival in STEMI patients. 
Methods: The study group consisted of 836 STEMI patients treated with primary percutaneous coro-
nary intervention (PCI). MVD was diagnosed in 52.3%, and CTO in 17.5% of patients. 
Results: In MVD patients, 30-day mortality was 4.8% (6.8% in the CTO and 3.8% in the non-CTO 
group, p = 0.167). After 6 years, of the 437 patients with MVD, 56 (38.6%) died in the CTO group, 
and 74 (25.4%) in the non-CTO group (p = 0.0055). CTO was an independent predictor of long-term 
mortality (OR 2.07, 95% CI 1.30–3.28, p = 0.002), whereas triple vessel disease was not (OR 1.27, 95% 
CI 0.78–1.97, p = 0.358). The other independent predictors of mortality were: age, anterior myocardial 
infarction, and PCI failure.
Conclusions: The presence of CTO is an independent predictor of the long-term mortality in STEMI 
patients treated with primary PCI. (Cardiol J 2017; 24, 2: 117–124)
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Introduction
In recent years  major developments in the 
treatment of patients with acute ST-segment el-
evation myocardial infarction (STEMI) have been 
observed. Rapid restoration of normal blood flow 
in the infarct-related artery (IRA) with primary 
angioplasty (percutaneous coronary intervention 
[PCI]) reduces the infarct size, preserves left 
ventricular function and improves patients’ clinical 
outcome [1]. In the setting of STEMI, the presence 
of multivessel disease (MVD) is an important risk 
factor indicating a worse prognosis [2, 3]. Accord-
ing to current guidelines primary PCI procedure is 
usually limited to IRA, leaving a substantial number 
of patients with incomplete revascularization [3]. 
While MVD is widely recognized as a risk factor, 
it is not clear whether the presence of a chronic 
total occlusion (CTO) in a non-IRA poses an ad-
ditional hazard to patients with STEMI. The aim of 
this study was to assess the impact of MVD, with 
particular emphasis on CTO, on short and long-
-term prognosis of patients with STEMI treated 
with primary PCI.
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Methods
Study design, objectives  
and patient selection
This study is a part of prospective registry of 
consecutive patients diagnosed with acute STEMI, 
treated with primary PCI at University Hospital 
in Poznan.
Consecutive patients, admitted between Octo-
ber 2001 and December 2003 were enrolled if they 
met the following inclusion criteria: typical chest 
pain persisting for more than 30 min and persistent 
ST-segment elevation in at least two contiguous 
leads: > 0.2 mV in leads V2–V3, or > 0.1 mV in 
other leads, or the presence of a new left bundle 
branch block. For this analysis patients treated with 
fibrinolysis prior to PCI  were excluded, unconscious 
patients in cardiogenic shock, those with critical 
stenosis of the left main coronary artery, as well 
as patients treated later than 12 h from symptom 
onset. The study was performed according to the 
provisions of the Declaration of Helsinki and good 
clinical practice. Informed consent was obtained 
from each patient. The study obtained the approval 
of local Ethics Committee (protocol no 807A/01).
Procedures and follow-up
On admission all aspirin, and clopidogrel-
naive patients received a loading dose of both 
drugs, 300 mg each. The primary PCI procedure 
was performed via femoral approach in accord-
ance with the standards of the time. After femoral 
puncture, patients were given a bolus of unfrac-
tionated heparin in a dose of 100 U/kg. The use 
of abciximab was at the discretion of the operator. 
The flow in coronary arteries was assessed by 
Thrombolysis In Myocardial Infarction (TIMI) 
scale. Significant stenosis of coronary artery was 
diagnosed if diameter stenosis was equal to or 
greater than 70% by visual estimate. IRA location 
was diagnosed upon the electrocardiogram (ECG) 
findings and the typical angiographic image. Single 
vessel disease (SVD) was diagnosed if significant 
stenosis was found exclusively in the IRA. MVD 
was defined as ≥ 70% diameter stenosis in one or 
more additional major epicardial vessel or their 
major branches. A CTO was defined as a non-IRA 
vessel being completely occluded, with no flow or 
TIMI 1 flow, and a typical angiographic image of 
chronically occluded artery. In all patients PCI was 
limited exclusively to the IRA. Standard catheters 
and bare metal stents were used during procedures. 
No aspiration thrombectomy devices were used. 
The PCI procedure was regarded as successful if 
final TIMI flow in the IRA was ≥ 2, with no major 
complication during the procedure. On discharge 
all patients were recommended to remain on dual 
antiplatelet therapy for 12 months, and then life-
long on aspirin alone.
Study end points
The main outcome measures were 30-day, 
12-month, and 6-year all-cause mortality rate 
among study patients. Additionally in-hospital, 
30-day, 12-, and 24-month major adverse cardio-
vascular events were analysed, including death of 
any cause, cardiovascular death, stroke, recurrent 
myocardial infarction (MI) (defined as any spon-
taneous event with persistent ST-segment eleva-
tion and/or new Q-wave formation, or the CK-MB 
rise 3 times above the limit), and target-vessel 
revascularization. Patient outcomes at 30 days, 
12 and 24 months were assessed by direct visits or 
telephone contact. The long-term all-cause mor-
tality data were obtained from the Polish National 
Identification Number Registry (PESEL). None of 
the patients was lost to the long-term follow-up.
Statistical analysis
All continuous variables are presented as 
means ± standard deviation or medians, and were 
compared using a Student t-test. Categorical vari-
ables are presented as counts and percentages or 
frequencies, and were compared using a c2 test. 
Survival curves were plotted using Kaplan-Meier 
method, and comparisons between groups were 
done using the log-rank test. The Cox proportional-
hazards model was used to identify the independent 
predictors of mortality. Predictors were selected 
at p < 0.1 in univariate analysis. The significant 
factors were calculated and expressed as adjusted 
hazard ratio (HR), with  95% confidence interval 
(CI). All probability values < 0.05 were considered 
significant. Statistical analysis was performed using 
the statistical package STATISTICA 8.1 PL.
Results
Patient population
Between October 2001 and December 2003 
a total of 1070 STEMI patients were admitted to 
the aforementioned department and treated with 
primary PCI. Of those, 836 met all the inclusion/ 
/exclusion criteria and constitute this study group. 
The baseline demographics and clinical charac-
teristics of the entire population is presented in 
Table 1. Table 2 summarizes lesion and procedural 
characteristics of the overall group.
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On baseline coronary angiography SVD was 
diagnosed in 399 (47.7%) patients, and MVD in 
437 (52.3%), of whom 262 had double-, and 175 
triple-vessel disease (31.3% and 20.9%, respec-
tively). The presence of chronically occluded 
non-IRA was found in 146 patients. Final TIMI 
flow ≥ 2 was achieved in 791 (94.6%) patients. 
Thirty-day, and 12-month mortality rate was 31 
(3.7%), and 65 (7.8%), respectively. Within the 
first 12 months recurrent MI occurred in 47 (5.6%) 
patients, stroke in 15 (1.8%), and target-vessel 
revascularization in 72 (8.6%). Additionally, 155 
(18.5%) patients underwent repeated PCI of non-
infarct-related vessel. Surgical revascularization 
(coronary artery bypass grafting [CABG]) was 
performed in 17 (2%) patients.The mean and the 
median time of observation time was 74 ± 27 and 
83 months, respectively. During this time 193 
(23.1%) patients died — 63 (15.8%) in SVD group, 
and 130 (29.7%) in MVD group, p < 0.0001. The 
following risk factors correlated significantly with 
all-cause mortality: age (OR 1.06, 95% CI 1.04–1.0, 
p < 0.0001), history of MI (1.6, 95% CI 1.14–2.43, 
p = 0.008), diabetes mellitus (OR 1.64, 95% CI 
1.09–2.47, p = 0.016), the presence of MVD (OR 
2.25, 95% CI 1.60–3.16, p < 0.0001), CTO (OR 
2.51, 95% CI 1.71–3.68, p < 0.0001), and PCI 
failure (OR 4.23, 95% CI 2.20–8.14, p < 0.0001). 
Anterior location of MI has shown borderline sig-
nificance (OR 1.34, 95% CI 0.97–1.85, p = 0.072). 
In multivariate analysis diabetes mellitus, previ-
ous MI, and the presence of MVD were no longer 
significant predictors of death, and only the age, 
CTO and PCI failure remained significant (Table 3). 
Kaplan-Meier survival curves of patients with 
SVD, and MVD with or without the presence of 
CTO are presented in Figure 1.
Results of multivariate analyses are pre-
sented in Table 4. The presence of CTO was not 
an independent predictor of short-term mortality. 
Nevertheless, the longer the observation time, the 
greater the predictive value of CTO. Importantly, 
a similar relationship could not be found for the 
presence of MVD, which per se did not correlate 
with mortality during any observation time.
Analysis of patients with MVD
Of 437 patients with MVD in 146 the presence 
of CTO was found. Patients in the CTO group, as 
compared non-CTO group, had a significantly more 
frequent history of MI and PCI procedure, signifi-
Table 1. Baseline demographics and clinical 
characteristics of the overall study group (n = 836).
Variable Patient-based
Age [years] 61.3 ± 11.7
Male 602 (72%)
Previous MI 165 (19.7%)
Hypertension 454 (54.3%)
Diabetes 135 (16.1%)
Current smoker 472 (56.5%)
Peripheral vessel disease 79 (9.4%)
History of PCI/CABG 47 (5.6%)/12 (1.4%)
CABG — coronary artery bypass grafting; MI — myocardial infarction; 
PCI — percutaneous coronary intervention.
Table 2. Procedural characteristics of the overall 
study group (n = 836).
Variable Patient-based
IRA
LAD 382 (45.7%)
LCX 109 (13.0%)
RCA 345 (41.3%)
MVD 437 (52.3%)
CTO 146 (17.5%)
CTO LAD 40 (4.8%)
CTO LCX 49 (5.8%)
CTO RCA 57 (6.8%)
IRA final TIMI flow ≥ 2 791 (94.6%)
CTO — chronic total occlusion; IRA — infarct-related artery;  
LAD — left anterior descending; LCX — left circumflex;  
MVD — multivessel disease; RCA — right coronary artery;  
TIMI — Thrombolysis In Myocardial Infarction
Table 3. Multivariate Cox proportional hazards 
analysis of long-term mortality of the overall 
study group (n = 836).
Variable OR 95% CI P
Age 1.06 1.04–1.08 < 0.0001
Chronic total  
occlusion
2.41 1.59–3.63 < 0.0001
PCI failure 3.42 1.68–6.97 0.0006
Multivessel  
disease
1.39 0.93–2.09 0.103
Anterior MI 1.41 0.99– 2.01 0.052
CI — confidence interval; MI — myocardial infarction; OR — odds 
ratio; PCI — percutaneous coronary intervention
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Table 4. Multivariate Cox proportional hazards analysis of all-cause mortality in subsequent periods of 
observation in the whole group (n = 836).
Observation time Age PCI failure CTO MVD Anterior MI
30 days
OR
95% CI
p 
1.06
1.02–1.10
0.0003
2.07
0.64–6.71
0.222
2.18
0.85–5.58
0.103
1.23
0.50–3.05
0.640
1.69
0.79–3.60
0.171
12 months 
OR
95% CI
p 
1.04
1.02–1.07
0.0001
3.75
1.64–8.58
0.002
2.22
1.21–4.08
0.009
1.11
0.58–2.14
0.737
2.23
1.28–3.87
0.004
24 months 
OR
95% CI
p 
1.05
1.03–1.08
< 0.0001
3.26
1.50–7.09
0.003
2.26
1.34–3.82
0.002
1.1
0.63–1.92
0.715
2.17
1.35–3.49
0.001
6 years
OR
95% CI
p 
1.06
1.03–1.06
< 0.0001
3.42
2.2–3.12
0.0006
2.41
1.35–2.05
< 0.0001
1.39
0.93–2.09
0.103
1.33
0.99–2.01
0.052
CI — confidence interval; CTO — chronic total occlusion; MI — myocardial infarction; MVD — multivessel disease; OR — odds ratio;  
PCI — percutaneous coronary intervention
Figure 1. Kaplan-Meier survival curves of patients with single, and multivessel disease (MVD) with and without the 
presence of chronic total occlusion (CTO); SVD — single vessel disease.
cantly less often anterior location of MI, as well 
they were more likely to have diabetes, although 
this difference was not statistically significant. 
TIMI flow ≥ 2 was achieved in 92.4% of patients 
with MVD; 93.5% in non-CTO vs. 90.4% in the 
CTO group (p = 0.177), whereas TIMI 3 flow was 
achieved in 87.6% of non-CTO patients and in 
84.2% of the CTO patients (p = 0.210) (Table 5).
Thirty-day mortality rate of MVD cohort was 
4.8% (21 patients). The rate of death in the CTO 
group was almost double the rate of the non-CTO 
group (6.8% vs. 3.8%), although this difference 
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was not statistically significant (p = 0.167). In 
a multivariate analysis only patient age was an in-
dependent predictor of 30-day mortality (OR 1.07, 
95% CI 1.01–1.11, p = 0.005).
After 1 year total, cardiac mortality rate was 
11% (48 patients), and 10% (44 patients), re-
spectively. Both total and cardiac mortality were 
significantly higher in the CTO group: for cardiac 
mortality 22 (15.1%) vs. 22 (7.6%), p = 0.015, 
for all-cause mortality 23 (15.8%) vs. 25 (8.6%), 
p = 0.026. After 6 years 129 (29.7%) patients 
died, of whom 56 (38.6%) in the CTO group, and 
74 (25.4%) in the non-CTO group (p = 0.0055). 
In univariate analysis we found the following 
significant risk factors of long-term all-cause mor-
tality: patient’s age (OR 1.05, 95% CI 1.02–1.08, 
p = 0.0001), the presence of triple-vessel disease 
(OR 1.63, 95% CI 1.07–2.48, p = 0.019), CTO (OR 
1.82, 95% CI 1.19–2.82, p = 0.005), and PCI failure 
(OR 3.69, 95% 1.70–8.00 CI, p = 0.0008). Anterior 
location of MI has shown borderline significance 
(OR 1.42, 95% CI 0.94–2.15, p = 0.093). Results 
of multivariate analysis in subsequent periods of 
observation are presented in Table 6. The pres-
ence of CTO was not an independent predictor of 
short-term mortality. Nevertheless, the longer the 
observation time, the greater the predictive value 
of CTO. It is important to note, a similar relation-
ship could not be found for the presence of triple-
vessel disease, which proved to be an independent 
Table 6. Multivariate Cox proportional hazards analysis of all-cause mortality in subsequent periods of 
observation in patients with multivessel disease (n = 437).
Observation time Age PCI failure CTO 3VD Anterior MI
30 days OR 1.07 1.85 1.88 2.39 1.43
95% CI 1.01–1.11 0.45–7.52 0.70–5.03 0.88–6.47 0.80–3.21
p 0.005 0.384 0.202 0.085 0.325
12 months OR 1.03 4.38 1.88 2.16 1.55
95% CI 1.00–1.06 1.77–10.84 0.96–3.65 1.09–4.26 0.83–2.91
p 0.041 0.001 0.061 0.026 0.165
24 months OR 1.05 4.02 2.06 1.32 1.88
95% CI 1.02–1.08 1.69–9.56 1.15–3.71 0.72–2.40 1.05–3.36
 p < 0.0001 0.001 0.015 0.355 0.032
6 years OR 1.06 3.48 2.07 1.24 1.57
95% CI 1.03–1.08 1.52–7.98 1.30–3.28 0.78–1.97 1.00–2.44
p < 0.0001 0.003 0.045 0.358 0.045
CI — confidence interval; CTO — chronic total occlusion; MI — myocardial infarction OR — odds ratio; 3VD — triple vessel disease;  
PCI — percutaneous coronary intervention
Table 5. Baseline demographics and clinical characteristics of patients with multivessel disease (MVD) 
(n = 437)
Total MVD  
(n = 437)
Non-CTO group  
(n = 291)
CTO group  
(n = 146)
P  
(non-CTO vs. CTO)
Age [years] 63.1 ± 11.7 63.6 ± 11.3 62.5 ± 11.2 0.335
Previous MI 116 (26.5%) 56 (19.2%) 60 (41.1%) < 0.0001
History of PCI 28 (6.4%) 9 (3.1%) 19 (13.0%) 0.0001
Diabetes 92 (21.1%) 54 (18.6%) 38 (26.0%) 0.074
Current smoker 235 (57.8%) 151 (51.9%) 84 (57.5%) 0.269
Hypertension 252 (57.7%) 168 (57.7%) 84 (57.5%) 0.968
Anterior MI 195 (44.6%) 136 (46.7%) 59 (33.8%) 0.011
Final TIMI flow ≥ 2 404 (92.4%) 272 (93.5%) 132 (90.4%) 0.177
CTO — chronic total occlusion; MI — myocardial infarction; PCI — percutaneous coronary intervention; TIMI — Thrombolysis In Myocardial 
Infarction
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predictor of death only at 12 months. In a long-term 
follow-up, the significant independent predictors 
of all-cause mortality were patients’ age, anterior 
location of MI, PCI failure and the presence of CTO.
Discussion
Long-term clinical outcomes of a large cohort 
of STEMI patients treated with primary PCI were 
reported on. The main objective of the study was to 
determine the effect and the the extent of coronary 
artery disease, particularly the presence of CTO, 
on early and long-term survival. 
There were risk factors of early and late mor-
tality such as age, presence of MVD, CTO, anterior 
location of MI, and PCI failure. The main reason 
of the failure of PCI was due to slow- or no-flow 
in IRA. All the procedures were performed in the 
early years of this century, thus no thrombectomy 
devices were used at that time. In cases where sub-
optimal flow was obtained  bailout intracoronary ab-
ciximab injections were usually performed, some-
times in combination with verapamil, nitroprusside 
or adenosine. In later years, a new strategy was 
introduced using upfront high-dose intracoronary 
adenosine injections with more promising results 
[4]. MVD is a well-known risk factor in the death of 
patients with STEMI [2, 3]. Whether the presence 
of CTO plays an independent role is still a matter 
of debate. The present study group was not at 
high risk. In order to eliminate the impact of other 
powerful risk factors, the following patients were 
excluded: patients those in a coma, with cardio-
genic shock, significant left main stenosis, as well 
as those of whom reperfusion was achieved after 
12 h from symptom onset. This resulted in a low 
30-day mortality rate for the entire group (3.7%). 
This study, like many others, found that MVD was 
an important risk factor of death in patients with 
STEMI. However, after taking into account the 
presence of  CTO, the mere presence of MVD was 
no longer an independent predictor, nor was the 
presence of triple-vessel disease. Interestingly, 
the predicting power of CTO grew along with time. 
In the early period, most likely due to relatively 
low risk for the whole group, CTO had negligible 
or borderline impact on survival. Over the years, 
its relevance grew, being a very strong predictor 
of death after 6 years. Many recent papers pointed 
to the importance of  CTO in patients with STEMI. 
van der Schaaf et al. [5], in a 1-year observation 
of 1417 patients with STEMI reported that the 
presence of CTO was an independent risk factor 
of mortality, while the mere presence of MVD was 
not. What’s more, the mortality rate of patients 
with MVD but without CTO was comparable with 
the mortality of patients with SVD. The same con-
clusion could be drawn when looking at the Figure 1 
presented in this study. The survival curves of 
SVD patients, and patients with non-CTO MVD 
run initially very close to each other, and begin 
to separate only after 2 years. In a later study of 
the same group the authors evaluated the effects 
of CTO on long-term prognosis [6]. They also 
found that the presence of CTO, but not MVD 
alone, was associated with long-term mortality, 
even when early deaths were excluded from the 
analysis. Polish authors, in a population of 666 
STEMI patients with MVD, after 5 years of obser-
vation discovered that CTO was an independent 
predictor of mortality [7]. Importantly, the study 
group was a high risk one. On admission shock 
was diagnosed in 22% of CTO patients, whereas 
in those with non-CTO MVD in 11% (p = 0.0027). 
The CTO group had significantly worse TIMI flow 
after procedure, and significantly higher in-hospital 
mortality rate than the rest of the MVD group (21% 
vs. 6.3%, p < 0.0001). After 5 years mortality rate 
in the CTO group was almost twice as high as in 
the non-CTO patients with MVD (40% vs. 22%, 
p < 0.0001). Similar results have been reported by 
a Japanese group for a population of 417 patients 
with STEMI treated with primary PCI within 24 h 
from symptom onset [8]. The presence of CTO, 
(found in only 8% of patients), as in the previous 
analysis, was associated with a higher incidence 
of shock (25% vs. 11%, p < 0.05). Again, 30-day 
mortality rate was significantly higher in the CTO 
group (14.3% vs. 3.4%, p < 0.01). In the present 
population the presence CTO was found in 17% of 
all patients, and 33% of the MVD group. Knowing 
the results of previous studies, high-risk subjects 
were deliberately excluded to reduce the impact 
of other powerful predictors of mortality. Most 
likely that was the reason no independent effect 
of CTO could bedemonstrated on in-hospital and 
30-day mortality, although among patients with 
MVD 30-day mortality rate in the CTO group was 
almost twice as high as those without  CTO (6.8% 
vs. 3.8%, p = 0.167). Studies that also included 
patients in cardiogenic shock reported significantly 
higher early mortality in CTO group [7, 8]. In this 
study however, each subsequent observation pe-
riod the significance of CTO as a predictor grew, 
and after 1 year cardiac mortality was significantly 
higher in this group (15.1% vs. 7.6%, p = 0.015). 
Since then, the presence of CTO became an in-
dependent risk factor of mortality, with a much 
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stronger impact on survival than the mere presence 
of MVD, which no longer played an independent 
role in patient outcome. 
This raises the question about the possible 
mechanisms responsible for a poorer prognosis of 
patients with STEMI and concomitant presence 
of  CTO. In the acute phase of STEMI the lack of 
sufficient collateral circulation to the IRA from the 
donor vessel being chronically occluded may play 
a significant role. This explains the higher incidence 
of cardiogenic shock in this group of patients, de-
scribed in the above-cited papers [6, 7]. In addition, 
as demonstrated in the present group, CTO pa-
tients are more likely to have a history of previous 
MI, hence poorer left ventricular function, which 
is one of the major predictors of poor prognosis 
[8, 9]. Moreover, prior to the index MI, IRA might 
have been a donor artery of collateral circulation to 
the myocardium supplied by the CTO vessel. Even 
after successful primary PCI, due to the damage 
of microvascular circulation, the collateral flow to 
this area may be permanently impaired [9, 10]. The 
question remains whether the results of this and 
other studies justify routine treatment aimed at 
complete revascularization, including the opening 
of chronically occluded arteries in STEMI patients. 
Since the current guidelines were released, the 
PRAMI and CvLPRIT trials have shown improved 
outcomes with a comprehensive approach [11, 
12]. This question is even more problematic re-
garding CTO lesions. During the 80s and 90s of 
the last century, due to the limited success rate 
of PCI procedures, majority of CTO lesions were 
left untreated or alternatively patients with MVD 
were referred to CABG. In recent years, owing to 
major developments in PCI techniques, significant 
improvement in outcomes of recanalization proce-
dures has been observed. In experienced centres 
the reported success rate is close to 90% [13, 14]. 
Multiple studies support the benefit of opening 
a CTO with regard to symptom relief [15]. Re-
covery of left ventricular function has also been 
reported, but this effect strongly depends on the 
presence of viable myocardium [16, 17]. Finally, 
increasingly more studies provide data on the role 
of CTO as an predictor of sudden cardiac death, and 
long-term mortality [18]. In a recent meta-analysis 
of 23 observational studies, Khan et al. [19]. found 
that successful recanalization of a CTO resulted in 
improved all-cause mortality, and lower rates of 
major adverse cardiac events. One of the possible 
explanations may be the favourable antiarrhythmic 
effect of successful recanalization of CTO. In re-
cently published paper Cetin et al. [20] demonstrat-
ed that after successful opening of the occluded 
vessel, ECG markers of ventricular repolarization 
inhomogeneity significantly improved, as compared 
with the pre-PCI values. Lee et al. [21] reported 
that in 60 out of 88 patients with CTO, in whom 
an attempt of PCI was made after the acute phase 
of MI, the procedure was successful in 40 (67%) 
patients. There were no deaths during follow-up 
in this successful group, while in patients in whom 
PCI failed or was not attempted death occurred in 
23% (p = 0.001). Thus, it may be concluded that the 
results of thisstudy add one more premise to the 
general agreement that each STEMI patient with 
CTO in non-culprit vessel should be considered 
for future procedures to ensure completeness of 
revascularization. In the present study 155 patients 
with MVD underwent PCI of vessel other than an 
IRA (18.5%) during the first year. Unfortunately, 
accurate data on how many recanalization attempts 
were made and what was the outcome of these 
procedures was not available
Limitations of the study
A major limitation of the study is that it was 
a non-randomized, observational, single centre 
design. The study patients were treated many 
years ago with techniques not recommended under 
current guidelines. Only bare metal stents were 
implanted and no aspiration thrombectomy devices 
were used during procedures. Another limitation of 
the study is the lack of data on left ventricular func-
tion, both on admission and after discharge from 
the hospital. The angiograms were not reviewed by 
a central angiographic core lab. Not all of the end-
points could be assessed and confirmed by direct 
visits; some of them were obtained by telephone 
contact. We do not know how many PCI procedures 
performed during the observation time concerned 
CTO vessels, and what the success rate was. 
Conclusions
The presence of CTO is an independent pre-
dictor of the long-term mortality in STEMI patients 
treated with primary PCI. The longer the observa-
tion time the more significant the impact of CTO 
has on survival.
The paper carries additional information on 
the importance of the presence of CTO in patients 
with coronary artery disease, and particularly with 
STEMI. In recent years, a major development in 
PCI techniques have been observed, especially 
regarding CTO procedures. This should prompt 
clinicians to carefully make evaluations of all 
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STEMI patients with regard to the indications of 
complete revascularization including chronically 
occluded vessels.
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